**RESIDENTIAL SCHOOL ON MEDICINAL CHEMISTRY:**
*Biology and Chemistry of Drug Discovery*
Drew University, Madison, New Jersey
June 7 – 11, 2010

**LECTURES**

“Strategic Issues in Drug Discovery”
“Enzyme Inhibition”
“Receptor Binding Assays”
“High-throughput Screening”
“Fragment-based Drug Design”
“Hit-to-Lead Process in Drug Discovery”
“Lead Discovery & Modification”
“Structure-based Drug Design”
“Drug-like Properties in Drug Discovery”
“Plasma Protein Binding”
“Preclinical Toxicology”
“G-Protein Coupled Receptors”
“Kinase Inhibitors”
“Drugs Affecting ION Channels”
“Clinical Development”

**FACULTY**

Prof. Magid Abou-Gharbia, *Temple University*
Eugene Cordes, Ph.D., *Vertex Pharmaceuticals*
Christopher Haber, Ph.D., *Pfizer Animal Health*
Jeffrey Hermes, Ph.D., *Merck*
Miles Congreve, Ph.D., *Heptares “Therapeutics*
Craig Lindsley, Ph.D., *Vanderbilt University*
Prof. Richard Silverman, *Northwestern University*
Jonathan Greer, Ph.D., *Abbott Laboratories*
Edward Kerns, Ph.D., *Pfizer*
George Trainor, Ph.D., *Bristol-Myers Squibb*
James MacDonald, Ph.D., *Chrysalis Pharma*
Jeff Reagan, Ph.D., *Amgen*
Andrew Tasker, Ph.D., *Amgen*
Prof. David J. Triggle, *SUNY Buffalo*
James McLeod, Ph.D., *Merck*

**SEMINARS**

“Drug Metabolism for Medicinal Chemists and Biologists”
“Molecular Modeling”
“Pharmacokinetics and ADME”

**FACULTY**

John Erve, Ph.D., *Pfizer*
Jonathan Greer, Ph.D., *Abbott Laboratories*
Cheryl Zimmerman, Ph.D., *University of MN*

**CASE HISTORIES**

“Eltrombopag”
“Preladenant”
“Ticagrelor”
“Telcagepant”

**FACULTY**

Kevin J. Duffy, Ph.D., *GlaxoSmithKline*
Andrew Stamford, Ph.D., *Merck*
Paul Willis., Ph.D., *AstraZeneca, UK*
Theresa Williams., Ph.D., *Merck*